Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26 2022 - 07:00AM
GlobeNewswire Inc.
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology
company developing induced pluripotent stem cell (iPSC)-derived
cell therapies in immuno-oncology, today announced that Lalo
Flores, Ph.D., Chief Executive Officer, will participate in a panel
titled “Next Generation Gene Editing” at Chardan’s 6th Annual
Genetic Medicines Conference on Monday, October 3, 2022, at 10:30
AM ET.
A live webcast of the event will be available on the Events
& Presentations page of Century’s website. A replay of the
webcast will be archived on the Company's website for a limited
time.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of
adult stem cells to develop curative cell therapy products for
cancer that we believe will allow us to overcome the limitations of
first-generation cell therapies. Our genetically engineered,
iPSC-derived iNK and iT cell product candidates are designed to
specifically target hematologic and solid tumor cancers. We are
leveraging our expertise in cellular reprogramming, genetic
engineering, and manufacturing to develop therapies with the
potential to overcome many of the challenges inherent to cell
therapy and provide a significant advantage over existing cell
therapy technologies. We believe our commitment to developing
off-the-shelf cell therapies will expand patient access and provide
an unparalleled opportunity to advance the course of cancer care.
For more information on Century Therapeutics please
visit www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking statements within
the meaning of, and made pursuant to the safe harbor provisions of,
The Private Securities Litigation Reform Act of 1995. In some
cases, you can identify forward-looking statements by terms such as
“may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,”
“anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “forecast,”
“potential” or “continue” or the negative of these terms or other
similar expressions. These statements are not guarantees of future
performance These risks and uncertainties are described more fully
in the “Risk Factors” section of our most recent filings with the
Securities and Exchange Commission and available at www.sec.gov.
You should not rely on these forward-looking statements as
predictions of future events. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur, and actual results could differ materially from those
projected in the forward-looking statements. Except as required by
applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
For More Information: Company: Elizabeth
Krutoholow – investor.relations@centurytx.comInvestors: Melissa
Forst/Maghan Meyers – century@argotpartners.comMedia: Joshua R.
Mansbach – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From May 2023 to Jun 2023
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Jun 2022 to Jun 2023